Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

With a career that spans continents, Prof. Dedee Murrell stands out as a global leader in dermatology and a passionate advocate for women in medicine. In this episode, we sit down together to explore her inspiring journey—from her early years in the UK and medical training in the USA to pioneering therapies for some of dermatology’s rarest and underserved conditions in Australia. We also reflect on her recent MDS Lifetime Achievement Award and discuss the value of mentorship, strategies for advancing a career in dermatology and academic medicine, and how to stay at the cutting edge of medical innovation.

Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting approximately 10–30% of children worldwide. Early-onset AD, which often emerges by age two, is associated with a higher risk of developing other allergic diseases such as asthma and food allergies. Beyond its physical burden, AD significantly impacts patients and their families, contributing to sleep disturbances, emotional distress, financial burdens, and social challenges.

An expert in paediatric dermatology provides guidance on managing patients with epidermolysis bullosa

In an encouraging development for children with severe atopic dermatitis (AD), dupilumab, an interleukin-4 (IL-4) receptor alpha antagonist, has shown evidence of improving height outcomes. According to new findings presented by Prof. Alan Irvine (Trinity College Dublin, Ireland) at the 2024 ...

Watch expert dermatologists discuss the management of moderate-to-severe AD in children and adolescents.

Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

Watch three experts discuss how they manage moderate-to-severe atopic dermatitis in children.

Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children's Hospital of Chicago, Chicago, IL, USA) about the key takeaways from the LIBERTY AD PRESCHOOL and the ongoing open-label extension trial, which is investigating the safety of dupilumab treatment in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.